Moderna

News

Moderna may be facing regulatory uncertainty in the US for its vaccine pipeline, but at least its clinical data is hitting the right notes.

News

The label for Moderna's RSV vaccine mResvia has been expanded to include adults aged 18 and over in the US, but will that lead to an uptick in sales?

News

HHS cancels funding for Moderna's pandemic flu vaccine development in a move viewed by some as an attack on mRNA technology.

News

The FDA has instructed Pfizer and Moderna to add stronger warnings to the labels of their COVID-19 vaccines about the risk of cardiotoxicity.

News

GSK and Pfizer could see a resurgence in sales of their RSV vaccines if new recommendations at a CDC expert meeting are confirmed by agency leaders.

News

Despite a steep fall-off in sales of RSV vaccine Arexvy last year, GSK has raised its long-term sales forecast to £40 billion in 2031.